HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.
Stocks · News reference
Halper Sadeh LLC Investigates Silence Therapeutics plc Acquisition
Investor rights law firm Halper Sadeh LLC is investigating whether the proposed acquisition of Silence Therapeutics plc by Merck KGaA provides fair value to shareholders.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq Jumps Over 1% As Tech Stocks Gain: Investor Sentiment Improves, Greed Index Remains In ‘Extreme Fear’ Zone
Market sentiment improved slightly but stayed in extreme fear. Nasdaq rose 1.11%, while Silence Therapeutics surged 126% on Merck deal.
Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.